202 related articles for article (PubMed ID: 12407133)
1. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
Pelak BA; Citron DM; Motyl M; Goldstein EJ; Woods GL; Teppler H
J Antimicrob Chemother; 2002 Nov; 50(5):735-41. PubMed ID: 12407133
[TBL] [Abstract][Full Text] [Related]
2. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
[TBL] [Abstract][Full Text] [Related]
3. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.
Pelak BA; Woods GL; Teppler H; Friedland I; Bartizal K; Motyl M
J Chemother; 2002 Jun; 14(3):227-33. PubMed ID: 12120874
[TBL] [Abstract][Full Text] [Related]
5. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.
Aldridge KE
Diagn Microbiol Infect Dis; 2002 Oct; 44(2):181-6. PubMed ID: 12458126
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections.
Pelak BA; Bartizal K; Woods GL; Gesser RM; Motyl M
Diagn Microbiol Infect Dis; 2002 Jun; 43(2):129-33. PubMed ID: 12088620
[TBL] [Abstract][Full Text] [Related]
8. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
Friedland I; Mixson LA; Majumdar A; Motyl M; Woods GL
J Chemother; 2002 Oct; 14(5):483-91. PubMed ID: 12462428
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell K; Fernandez H
J Antimicrob Chemother; 2001 Nov; 48(5):641-51. PubMed ID: 11679553
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
Behra-Miellet J; Dubreuil L; Calvet L
Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of anaerobic bacteria in Australia.
Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
[TBL] [Abstract][Full Text] [Related]
14. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
[TBL] [Abstract][Full Text] [Related]
15. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell KL; Gesser RM
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S119-25. PubMed ID: 12173120
[TBL] [Abstract][Full Text] [Related]
16. Susceptibilities of bovine summer mastitis bacteria to antimicrobial agents.
Jousimies-Somer H; Pyörälä S; Kanervo A
Antimicrob Agents Chemother; 1996 Jan; 40(1):157-60. PubMed ID: 8787898
[TBL] [Abstract][Full Text] [Related]
17. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
18. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
Solomkin J; Teppler H; Graham DR; Gesser RM; Meibohm AR; Roy S; Woods GL
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii51-7. PubMed ID: 15150183
[TBL] [Abstract][Full Text] [Related]
19. Ertapenem: a review of its use in the management of bacterial infections.
Curran M; Simpson D; Perry C
Drugs; 2003; 63(17):1855-78. PubMed ID: 12921489
[TBL] [Abstract][Full Text] [Related]
20. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.
Citron DM; Goldstein EJ; Merriam CV; Lipsky BA; Abramson MA
J Clin Microbiol; 2007 Sep; 45(9):2819-28. PubMed ID: 17609322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
